Related Experiment Video

Updated: Jun 17, 2025

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

19.1K

Exploring the causal relationship: bidirectional mendelian randomization study on benign prostatic hyperplasia and

Nanyan Xiang1, Shiqi Su1, Zeng Wang2

  • 1Department of Urology, Innovation Institute for Integration of Medicine and Engineering, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Chengdu, Sichuan, China.

Frontiers in Genetics
|August 12, 2024
PubMed

Insights

Benign prostatic hyperplasia (BPH) may increase the risk of coronary heart disease (CHD) and myocardial infarction (MI). However, BPH might offer protection against stroke, though further research is needed to confirm these cardiovascular disease (CVD) links.

Area of Science:

  • Cardiovascular Science
  • Urology
  • Genetics

Background:

  • Benign prostatic hyperplasia (BPH) is prevalent in aging men.
  • Cardiovascular diseases (CVDs) are a leading global cause of mortality.
  • Observational studies suggest a link between BPH and CVDs, but causality remains uncertain.

Purpose of the Study:

  • To investigate the potential causal relationship between Benign prostatic hyperplasia (BPH) and five major cardiovascular diseases (CVDs).
  • Specifically examining stroke, coronary heart disease (CHD), heart failure, myocardial infarction (MI), and atrial fibrillation (AF).

Main Methods:

  • A bidirectional two-sample Mendelian randomization (MR) study was employed.
  • Genetic data for BPH and CVDs were sourced from large-scale population databases (UK Biobank, HERMES, FinnGen).
  • Sensitivity analyses included MR-Egger, MR-PRESSO, and weighted median methods to ensure robustness.

Main Results:

  • Benign prostatic hyperplasia (BPH) was associated with an increased risk of coronary heart disease (CHD) and myocardial infarction (MI).
  • A decreased risk of stroke was observed in individuals with BPH.
  • No statistically significant causal association was found in the reverse analysis (CVDs influencing BPH).

Conclusions:

  • The study indicates a potential causal link between Benign prostatic hyperplasia (BPH) and cardiovascular diseases (CVDs).
  • BPH may act as a risk factor for CHD and MI, while potentially being protective against stroke.
  • Further investigation with larger sample sizes is recommended to elucidate these associations.
Abstract

Keywords:
benign prostatic hyperplasiacardiovascular diseasescausal relationshipgenetic epidemiologymendelian randomization

More Related Videos

How to Study Basement Membrane Stiffness as a Biophysical Trigger in Prostate Cancer and Other Age-related Pathologies or Metabolic Diseases13:18

How to Study Basement Membrane Stiffness as a Biophysical Trigger in Prostate Cancer and Other Age-related Pathologies or Metabolic Diseases

Published on: September 20, 2016

9.7K
Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia08:38

Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia

Published on: August 28, 2013

25.2K

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
13.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
28
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
106
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
69